{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:38:54Z","timestamp":1794407934375,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016147","name":"Korean Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.aohep.2024.101749","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:17:58Z","timestamp":1733746678000},"page":"101749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial"],"prefix":"10.1016","volume":"30","author":[{"given":"Do Seon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6246-1783","authenticated-orcid":false,"given":"Jae Youn","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-5130","authenticated-orcid":false,"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.aohep.2024.101749_bib0001","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101749_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gut.2010.224097","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data","volume":"60","author":"Mathurin","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.aohep.2024.101749_bib0003","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2024.101749_bib0004","doi-asserted-by":"crossref","unstructured":"Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology 2018;155(2):458\u201368.e8. https:\/\/doi.org\/10.1053\/j.gastro.2018.05.011.","DOI":"10.1053\/j.gastro.2018.05.011"},{"issue":"17","key":"10.1016\/j.aohep.2024.101749_bib0005","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2024.101749_bib0006","doi-asserted-by":"crossref","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol 2020;72(3):558\u201377.","DOI":"10.1016\/j.jhep.2019.10.003"},{"key":"10.1016\/j.aohep.2024.101749_bib0007","doi-asserted-by":"crossref","unstructured":"Leclercq S, De Saeger C, Delzenne N, de Timary P, St\u00e4rkel P. Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence. Biol Psychiatry 2014;76(9):725\u201333. https:\/\/doi.org\/10.1016\/j.biopsych.2014.02.003.","DOI":"10.1016\/j.biopsych.2014.02.003"},{"key":"10.1016\/j.aohep.2024.101749_bib0008","doi-asserted-by":"crossref","unstructured":"Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology 2016;64(3):955\u201365. https:\/\/doi.org\/10.1002\/hep.28456.","DOI":"10.1002\/hep.28456"},{"key":"10.1016\/j.aohep.2024.101749_bib0009","doi-asserted-by":"crossref","unstructured":"Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol 2017;30(5):486\u201397. https:\/\/doi.org\/10.20524\/aog.2017.0178.","DOI":"10.20524\/aog.2017.0178"},{"issue":"3","key":"10.1016\/j.aohep.2024.101749_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.27779","article-title":"Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis","volume":"62","author":"Michelena","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2024.101749_bib0011","first-page":"36","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy (Los Angel)"},{"key":"10.1016\/j.aohep.2024.101749_bib0012","doi-asserted-by":"crossref","unstructured":"Torre A, C\u00f3rdova-Gallardo J, Frati Munari AC. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Ther Clin Risk Manag 2023;19:839\u201351. https:\/\/doi.org\/10.2147\/tcrm.S425292.","DOI":"10.2147\/TCRM.S425292"},{"issue":"7","key":"10.1016\/j.aohep.2024.101749_bib0013","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2024.101749_bib0014","doi-asserted-by":"crossref","unstructured":"Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol 2018;11:1756284818800307. https:\/\/doi.org\/10.1177\/1756284818800307.","DOI":"10.1177\/1756284818800307"},{"key":"10.1016\/j.aohep.2024.101749_bib0015","doi-asserted-by":"crossref","unstructured":"Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol 2018;11:1756284818800307. https:\/\/doi.org\/10.1177\/1756284818800307.","DOI":"10.1177\/1756284818800307"},{"key":"10.1016\/j.aohep.2024.101749_bib0016","doi-asserted-by":"crossref","unstructured":"Dong T, Aronsohn A, Gautham Reddy K, Te HS. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. Dig Dis Sci 2016;61(12):3621\u20136. https:\/\/doi.org\/10.1007\/s10620-016-4313-0.","DOI":"10.1007\/s10620-016-4313-0"},{"key":"10.1016\/j.aohep.2024.101749_bib0017","doi-asserted-by":"crossref","unstructured":"Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol 2018;113(2):175\u201394. https:\/\/doi.org\/10.1038\/ajg.2017.469.","DOI":"10.1038\/ajg.2017.469"},{"key":"10.1016\/j.aohep.2024.101749_bib0018","doi-asserted-by":"crossref","unstructured":"Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359(10):1018\u201326. https:\/\/doi.org\/10.1056\/NEJMoa0801209.","DOI":"10.1056\/NEJMoa0801209"},{"key":"10.1016\/j.aohep.2024.101749_bib0019","doi-asserted-by":"crossref","unstructured":"Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45(6):1348\u201354. https:\/\/doi.org\/10.1002\/hep.21607.","DOI":"10.1002\/hep.21607"},{"issue":"3","key":"10.1016\/j.aohep.2024.101749_bib0020","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","volume":"74","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2024.101749_bib0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41575-020-00376-3","article-title":"Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure","volume":"18","author":"Trebicka","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101749_bib0022","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2024.101749_bib0023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"Jim\u00e9nez","year":"2022","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2024.101749_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264278","article-title":"The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial","volume":"17","author":"Kimer","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.aohep.2024.101749_bib0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3350\/cmh.2020.0086","article-title":"From intestinal dysbiosis to alcohol-associated liver disease","volume":"26","author":"Mendes","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101749_bib0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2024.101749_bib0027","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"Llopis","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.aohep.2024.101749_bib0028","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101749_bib0029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jgh.13852","article-title":"Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: a randomized trial","volume":"33","author":"Kimer","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101749_bib0030","doi-asserted-by":"crossref","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2024.101749_bib0031","article-title":"Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome","volume":"11","author":"Yu","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/j.aohep.2024.101749_bib0032","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep4.1881","article-title":"Treatment with simvastatin and rifaximin restores the plasma metabolomic profile in patients with decompensated cirrhosis","volume":"6","author":"Pose","year":"2022","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.aohep.2024.101749_bib0033","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/apt.16200","article-title":"Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis","volume":"53","author":"Kim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.aohep.2024.101749_bib0034","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","article-title":"Alcohol, liver disease and the gut microbiota","volume":"16","author":"Bajaj","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101749_bib0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cld.2016.02.004","article-title":"Pathogenesis of alcoholic liver disease","volume":"20","author":"Dunn","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.aohep.2024.101749_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2022.0017","article-title":"Subclinical versus advanced forms of alcohol-related liver disease: need for early detection","volume":"29","author":"G\u00f3mez-Medina","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101749_bib0037","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","article-title":"The microbiota in cirrhosis and its role in hepatic decompensation","volume":"75","author":"Trebicka","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2024.101749_bib0038","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5009\/gnl20032","article-title":"Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update","volume":"15","author":"Fukui","year":"2021","journal-title":"Gut Liver"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124005325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124005325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:31:46Z","timestamp":1777782706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268124005325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1665268124005325"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101749","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C.","name":"copyright","label":"Copyright"}],"article-number":"101749"}}